http://rdf.ncbi.nlm.nih.gov/pubchem/patent/AU-2022247731-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_a8b6e2feb920f592f813feab94bf4134 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2300-00 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-36 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-60 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-64 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-4873 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-52 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0051 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-008 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-5575 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-22 |
| filingDate | 2022-10-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e02d689965fc436bfe086fe92adcb815 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6809d06a42af57c7818d70528456a0f0 |
| publicationDate | 2022-11-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | AU-2022247731-A1 |
| titleOfInvention | Drug delivery systems comprising a neurotrophic agent, an apoptosis signaling fragment inhibitor (FAS) or FAS ligand (FASL) inhibitor, a tumor necrosis factor-alpha (TNF-alpha) or TNF receptor inhibitor, a mitochondrial peptide, an oligonucleotide, a chemokine inhibitor, or a cysteine-aspartic protease |
| abstract | This disclosure relates to a drug delivery system comprising a neurotrophic agent, an napoptosis signaling fragment inhibitor (FAS) or FAS-ligand (FASL) inhibitor, a tumor n5 necrosis factor-a (TNF-a) or TNF receptor (TNFR) inhibitor, a mitochondrial peptide, an noligonucleotide, a chemokine inhibitor, or a cysteine-aspartic protease, including any ncombination of these compounds and, optionally, a sustained delivery component. This type nof drug delivery system can be used to treat a medical condition such as an inherited or agenrelated choroid, retina, optic nerve disorder, or optic nerve degeneration; an otic disorder; a n0 neurologic or CNS disorder; or a related condition; or a condition related to occlusion or nobstruction of a blood vessel or blood circulation such as a stroke, myocardial or renal ninfarction. Medicaments, methods of manufacturing medicaments, kits, and other related nproducts or methods are also described. |
| priorityDate | 2018-06-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 233.